Educational Intervention for HPV Vaccine Uptake
Recruiting in Palo Alto (17 mi)
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: University of Colorado, Denver
Disqualifiers: Non-English/Spanish speakers, Cognitive impairment, Vulnerable populations, others
No Placebo Group
Trial Summary
What is the purpose of this trial?The educational intervention to be delivered by the CHE(Community Health Educator) consists of "toolkit education materials" developed by the National Cancer Institute (NCI) and a small media intervention (i.e., video) that our research team has developed. The NCI-produced toolkit education materials consist of Power Point presentations, flyers, and posters that contain information about HPV(Human Papilloma Virus), HPV-related cancers, and the importance of the HPV vaccine series for adolescents (9-17 years old) and young adults (18-26 year old) who are eligible for the vaccine.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on educational materials about the HPV vaccine, so it's unlikely that your medications will be affected.
What data supports the effectiveness of the treatment HPV Educational Intervention for increasing HPV vaccine uptake?
Research shows that educational programs combined with strategies to improve healthcare practices can significantly increase HPV vaccine completion rates. For example, one study found that after implementing an educational program, HPV vaccine completion rates increased from 45% to 65% in a pilot program and from 62% to 94% in a follow-up phase.
12345Is the HPV Educational Intervention safe for humans?
The HPV vaccines, which are part of the educational intervention, have been studied extensively for safety. Research shows that while there are some adverse events (unwanted effects) reported, they are generally considered safe for use in humans.
16789How is the HPV Educational Intervention treatment different from other treatments for increasing HPV vaccine uptake?
The HPV Educational Intervention is unique because it focuses on educating health professional students and young people to increase their knowledge and acceptance of the HPV vaccine, rather than directly administering a vaccine or medication. This approach aims to improve vaccine uptake by addressing knowledge gaps and leveraging educational strategies tailored to specific groups, such as schools with low vaccination rates.
14101112Eligibility Criteria
This trial is for parents of Denver Health patients aged 9-17 who haven't started or completed the HPV vaccine series, and Denver Health patients themselves aged 18-26 in the same situation. Participants must speak English or Spanish and be willing to follow study procedures.Inclusion Criteria
Stated willingness to comply with all study procedures and be available for the duration of the study
Denver Health patients will be identified from one of the following clinics; Denver Health Clinics Eastside Adult Clinic, Eastside Women's Care Clinic, Westside Adult Clinic, Westside Women's Care Clinic, Pavilion C: Women's Care Clinic, La Casa-Quigg Newton Family Health Center, Lowry Family Health Center, Montbello Family Health Center, Westwood Family Health Center, Parkhill Family Health Center, Webb Center For Primary Care, Pena Southwest Clinic
I speak English or Spanish.
+2 more
Exclusion Criteria
I am under 18 years old.
I am able to make decisions for myself and am not impaired by substances or cognitive issues.
Individuals from vulnerable populations (e.g., inmates, homeless, pregnant women, and those with auditory impairment) [at the discretion of the CHE or PN upon recruitment]
+1 more
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Educational Intervention
Participants receive educational workshops delivered by a Community Health Educator using toolkit education materials and a small media intervention
1 day
1 visit (in-person)
Follow-up
Participants are monitored for vaccine uptake and completion through follow-up surveys conducted over the phone
6 months
2 follow-up calls (3 and 6 months post-intervention)
Participant Groups
The trial tests an educational program about HPV and its vaccine, using NCI toolkit materials like presentations, flyers, posters, plus a video developed by researchers. It aims to increase awareness and vaccination rates among eligible adolescents and young adults.
1Treatment groups
Experimental Treatment
Group I: Patients Eligible for HPV VaccineExperimental Treatment1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of Colorado HospitalDenver, CO
Loading ...
Who Is Running the Clinical Trial?
University of Colorado, DenverLead Sponsor
National Cancer Institute (NCI)Collaborator
References
A quality improvement initiative to increase HPV vaccine rates using an educational and reminder strategy with parents of preteen girls. [2015]A quality improvement project was undertaken to determine if an evidence-based educational brochure and reminder system can increase human papillomavirus (HPV) vaccine uptake and dose completion rates.
Evidence-Based Practice Model to Increase Human Papillomavirus Vaccine Uptake: A Stepwise Approach. [2022]To increase uptake of human papillomavirus (HPV) vaccination by implementing a stepwise evidence-based practice model to offer HPV education along with a strong provider recommendation to parents of youth and adolescents.
A quality improvement education initiative to increase adolescent human papillomavirus (HPV) vaccine completion rates. [2020]HPV vaccine uptake is low, nationwide. Quality improvement (QI) principles have the potential to change practice; however, not all providers are confident with QI skills. We developed an educational program designed to enhance QI skills and improve HPV vaccination rates. Five pediatric practices participated in the pilot initiative. Training consisted of presentations regarding QI methods, data tracking and analysis, and system changes to reduce missed opportunities. Monthly for 6 months, participants performed chart audits, captured data, printed run charts, and developed, implemented, and tracked interventions. Outcome measures included rates of HPV vaccine completion and missed opportunities. A second phase included eight different pediatric practices who received similar training. Outcome measures included rates of HPV vaccine initiation and completion. Over the 6 months, mean HPV vaccine completion rates increased (45% to 65%) and missed opportunities for HPV vaccination decreased (45% to 19%) in the pilot program. When the program was replicated in phase 2, an increase was seen in both HPV vaccine initiation (46% to 61%) and completion (62% to 94%) rates. Combining QI education with workflow-focused strategies was associated with a reduction in missed opportunities and a substantial increase in HPV vaccine completion rates.
Leveraging teachable moments in cancer prevention by improving HPV vaccination in health professional students (HPS): A systematic review. [2022]Vaccination against HPV is safe and effective in cancer prevention, yet vaccination uptake remains low. Strong recommendation of HPV vaccination by healthcare providers increases immunization rates, but gaps in knowledge persist surrounding HPV and HPV vaccination amongst health professional students (HPS). It is critical to educate HPS in all professions to maximize vaccination opportunities and increase vaccine uptake. The objective of this study is to evaluate evidence on HPV knowledge, vaccine uptake, and educational interventions in HPS to identify specific deficits to improve education.
Promoting Strategies to Increase HPV Vaccination in the Pediatric Primary Care Setting. [2022]Evaluation of a quality improvement project designed to improve HPV vaccine uptake in a pediatric primary care setting for young adolescents.
Safety of HPV vaccines in the age of nonavalent vaccination. [2018]To date three vaccines against human papilloma virus (HPV) have been licensed: a bivalent, a quadrivalent and, in 2014, a nonavalent vaccine. Despite the early implementation of national vaccination programs, in the majority of developed countries coverage rates remain unsatisfactory. Rumors about vaccine safety have been one of the principal obstacles for the acceptance of HPV vaccination by the public. It is therefore of primary importance to provide the public with clear and up-to-date information about HPV vaccination safety. To this aim, in this narrative review we will summarize safety data from pre and postlicensure studies for the three HPV vaccines available with a focus on the safety profile of the new nonavalent vaccine.
Adverse events associated with human papillomavirus vaccines: a protocol for systematic review with network meta-analysis incorporating all randomised controlled trials comparing with placebo, adjuvants and other vaccines. [2023]Adverse events following the injection (AEFIs) of human papillomavirus vaccine (HPVv) among female adolescents are still a major public health concern.
Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020. [2022]To evaluate the reporting rate of adverse events following immunization (AEFI) of the quadrivalent human papillomavirus vaccine (4vHPV) and to compare the reporting rate of AEFI following 4vHPV with those following other vaccines.
Adverse events following immunization in Ontario's female school-based HPV program. [2015]In September 2007, a school-based human papillomavirus (HPV) vaccination program targeting grade 8 girls (approximately 13 years old) and delivered by public health was implemented in Ontario, Canada. We assessed reports of adverse events following immunization (AEFI) from the school-based program as part of quadrivalent HPV (HPV4) vaccine safety surveillance and to contribute to a comprehensive HPV vaccine program evaluation.
Co-production of an educational package for the universal human papillomavirus (HPV) vaccination programme tailored for schools with low uptake: a participatory study protocol. [2021]To co-produce with young people an educational package about the human papillomavirus (HPV) vaccine that is tailored to increase vaccine uptake in schools and populations with lower uptake.
Effects of Educational Interventions on Human Papillomavirus Vaccine Acceptability: A Randomized Controlled Trial. [2021]To estimate whether targeted educational interventions can increase human papillomavirus (HPV) vaccine acceptability and knowledge among young women.
"The problem is not lack of information": A qualitative study of parents and school nurses' perceptions of barriers and potential solutions for HPV vaccination in schools. [2023]HPV vaccination has been offered in school programs for over a decade in Quebec, Canada, but the vaccine coverages are not reaching the target coverage in several regions. This qualitative study aimed to describe barriers and enabling conditions of HPV vaccination as perceived by parents and school nurses and identify potential solutions to improve HPV vaccine uptake rates and acceptance in school-based programs.